• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.

作者信息

Giugliano Dario, Longo Miriam, Caruso Paola, Scappaticcio Lorenzo, Pontillo Alessandro, Di Martino Nicole, Porcellini Chiara, Angelino Silvia, Caputo Mariangela, Bellastella Giuseppe, Maiorino Maria Ida, Esposito Katherine

机构信息

Department of Advanced Medical and Surgical Science, University of Campania "Luigi Vanvitelli", Naples, Italy.

Department of Life Sciences, Health and Health Professions, Link Campus University, Rome, Italy.

出版信息

Diabetologia. 2025 Aug 28. doi: 10.1007/s00125-025-06535-y.

DOI:10.1007/s00125-025-06535-y
PMID:40877579
Abstract
摘要

相似文献

1
BEYOND 4 years: simplification of complex insulin regimens with a fixed-ratio combination of basal insulin plus a GLP-1 receptor agonist or basal insulin plus an SGLT-2 inhibitor.4年以上：使用基础胰岛素与胰高血糖素样肽-1受体激动剂的固定比例组合或基础胰岛素与钠-葡萄糖协同转运蛋白2抑制剂的固定比例组合简化复杂胰岛素治疗方案。
Diabetologia. 2025 Aug 28. doi: 10.1007/s00125-025-06535-y.
2
BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.2 年以上：通过简化复杂的 2 型糖尿病胰岛素方案，实现代谢益处的持久性。
Endocrine. 2024 Feb;83(2):399-404. doi: 10.1007/s12020-023-03547-9. Epub 2023 Oct 3.
3
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial.简化从基础-餐时胰岛素方案到基础胰岛素加 GLP-1RA 或基础胰岛素加 SGLT2 抑制剂的固定比例配方的可行性：BEYOND，一项随机、实用试验。
Diabetes Care. 2021 Jun;44(6):1353-1360. doi: 10.2337/dc20-2623. Epub 2021 Apr 21.
4
Practical limitations of complex insulin therapies in type 2 diabetes: Focus on therapy simplification using fixed-ratio combinations of basal insulin and a glucagon-like peptide-1 receptor agonist.2型糖尿病复杂胰岛素治疗的实际局限性：聚焦于使用基础胰岛素与胰高血糖素样肽-1受体激动剂的固定比例组合简化治疗方案
Diabetes Obes Metab. 2025 Aug;27 Suppl 7:42-54. doi: 10.1111/dom.16645. Epub 2025 Jul 28.
5
Impact of real-time glucose monitoring using FreeStyle Libre 3 on glycaemia in type 2 diabetes managed with basal insulin plus SGLT2 inhibitor and/or GLP-1 agonist: the FreeDM2 randomised controlled trial protocol.使用FreeStyle Libre 3进行实时血糖监测对基础胰岛素联合SGLT2抑制剂和/或GLP-1激动剂治疗的2型糖尿病患者血糖水平的影响：FreeDM2随机对照试验方案
BMJ Open. 2025 Apr 15;15(4):e090154. doi: 10.1136/bmjopen-2024-090154.
6
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.胰岛素和胰高血糖素样肽 1 受体激动剂联合治疗 2 型糖尿病：随机对照试验的系统评价和荟萃分析。
Diabetes Care. 2017 Apr;40(4):614-624. doi: 10.2337/dc16-1957.
7
Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.胰高血糖素样肽-1 受体激动剂与基础胰岛素联合治疗 2 型糖尿病的系统评价和荟萃分析。
Lancet. 2014 Dec 20;384(9961):2228-34. doi: 10.1016/S0140-6736(14)61335-0. Epub 2014 Sep 11.
8
An overview of randomized clinical trials of fixed-ratio combinations of basal insulin plus GLP-1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes.基础胰岛素与胰高血糖素样肽-1受体激动剂固定比例组合的随机临床试验综述（注射疗法）：2型糖尿病患者推进治疗的经验教训
Diabetes Obes Metab. 2025 Aug;27 Suppl 7:14-25. doi: 10.1111/dom.16616. Epub 2025 Jul 17.
9
Basal insulin plus GLP-1 RA or SGLT2 inhibitor was noninferior to basal-bolus insulin intensification for HbA in T2DM.基础胰岛素联合 GLP-1RA 或 SGLT2 抑制剂与基础-餐时胰岛素强化治疗相比在 T2DM 患者中HbA 不劣效。
Ann Intern Med. 2021 Sep;174(9):JC106. doi: 10.7326/ACPJ202109210-106. Epub 2021 Sep 7.
10
What is the 'real-world' experience with fixed-ratio combination therapy (insulin + GLP-1 receptor agonist) in routine clinical practice? Take-home messages for clinicians regarding key outcomes.在常规临床实践中，固定比例联合治疗（胰岛素+GLP-1受体激动剂）的“真实世界”经验是什么？给临床医生关于关键结果的实用信息。
Diabetes Obes Metab. 2025 Aug;27 Suppl 7:26-41. doi: 10.1111/dom.16593. Epub 2025 Jul 10.

本文引用的文献

1
Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment.胰高血糖素样肽-1受体激动剂与基础胰岛素的固定比例联合用药：简化2型糖尿病治疗
Endocrine. 2025 Apr 24. doi: 10.1007/s12020-025-04243-6.
2
BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes.2 年以上：通过简化复杂的 2 型糖尿病胰岛素方案，实现代谢益处的持久性。
Endocrine. 2024 Feb;83(2):399-404. doi: 10.1007/s12020-023-03547-9. Epub 2023 Oct 3.
3
Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes.
专家小组关于简化复杂胰岛素治疗方案以改善2型糖尿病治疗效果的指南及叙述性综述
Diabetes Ther. 2022 Apr;13(4):619-634. doi: 10.1007/s13300-022-01222-2. Epub 2022 Mar 11.
4
Feasibility of Simplification From a Basal-Bolus Insulin Regimen to a Fixed-Ratio Formulation of Basal Insulin Plus a GLP-1RA or to Basal Insulin Plus an SGLT2 Inhibitor: BEYOND, a Randomized, Pragmatic Trial.简化从基础-餐时胰岛素方案到基础胰岛素加 GLP-1RA 或基础胰岛素加 SGLT2 抑制剂的固定比例配方的可行性：BEYOND，一项随机、实用试验。
Diabetes Care. 2021 Jun;44(6):1353-1360. doi: 10.2337/dc20-2623. Epub 2021 Apr 21.
5
Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.胰岛素和胰高血糖素样肽 1 受体激动剂联合治疗 2 型糖尿病：随机对照试验的系统评价和荟萃分析。
Diabetes Care. 2017 Apr;40(4):614-624. doi: 10.2337/dc16-1957.
6
Achievement of goals in U.S. diabetes care, 1999-2010.美国糖尿病护理目标的实现，1999-2010 年。
N Engl J Med. 2013 Apr 25;368(17):1613-24. doi: 10.1056/NEJMsa1213829.
7
Efficacy of insulin analogs in achieving the hemoglobin A1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.胰岛素类似物在 2 型糖尿病中实现 <7% 的血红蛋白 A1c 目标的疗效：随机对照试验的荟萃分析。
Diabetes Care. 2011 Feb;34(2):510-7. doi: 10.2337/dc10-1710. Epub 2011 Jan 7.